172 In the index

Teriparatide TERI

An FDA-approved medication (Forteo) for severe osteoporosis, notable for actually building new bone rather than just slowing bone loss. Human studies confirm real increases in bone density and lower fracture risk, though it's typically used for a limited time due to a bone-tumor signal seen in rat studies at high, prolonged doses.

Also known as Forteo, PTH 1-34, Teriparatida, Teriparatidum, 1-34-Human PTH, Human PTH (1-34), LY 333334, 10T9CSU89I, TERIPARATIDE RECOMBINANT HUMAN

Effects Heal

Routes Subcutaneous

Legal status Prescription drug

WADA Banned at all times

Molecular Structure of C₁₈₁H₂₉₁N₅₅O₅₁S₂

Drag to rotate · scroll to zoom

PubChem has no 3D conformer for this molecule, so this is the flat structure.

Chemistry

Formula: C181H291N55O51S2
Molar mass: 4118
CAS: 52232-67-4
PubChem CID: 16133850
IUPAC name: (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]hexanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(1S)-1-carboxy-2-phenylethyl]amino]-1,4-dioxobutan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
InChIKey: OGBMKVWORPGQRR-UMXFMPSGSA-N

Reported dosing

Approved label

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose 20 mcg/day

Reported range 20 mcg/day (standard approved dose)

Route Subcutaneous injection

Frequency Once daily

Duration Up to 2 years (lifetime maximum, per FDA labeling)

FDA-approved (Forteo) for severe osteoporosis; carries a boxed warning limiting lifetime duration of use due to a bone-tumor signal in rat studies.

Where this comes from FDA prescribing information

These figures are recorded for reference and are not a recommendation. Dosing is a decision for you and a clinician.